These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16840706)

  • 1. Is Huntington's a glutamine storage disease?
    Brusilow WS
    Neuroscientist; 2006 Aug; 12(4):300-4. PubMed ID: 16840706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
    Truant R; Atwal RS; Burtnik A
    Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
    Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
    Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huntingtin-protein interactions and the pathogenesis of Huntington's disease.
    Li SH; Li XJ
    Trends Genet; 2004 Mar; 20(3):146-54. PubMed ID: 15036808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation.
    Behrens PF; Franz P; Woodman B; Lindenberg KS; Landwehrmeyer GB
    Brain; 2002 Aug; 125(Pt 8):1908-22. PubMed ID: 12135980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias.
    Trottier Y; Lutz Y; Stevanin G; Imbert G; Devys D; Cancel G; Saudou F; Weber C; David G; Tora L
    Nature; 1995 Nov; 378(6555):403-6. PubMed ID: 7477379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
    Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K
    Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease.
    Lee WC; Yoshihara M; Littleton JT
    Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3224-9. PubMed ID: 14978262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease.
    Dasgupta S; Fishman MA; Mahallati H; Castro LM; Tashima AK; Ferro ES; Fricker LD
    PLoS One; 2015; 10(12):e0145333. PubMed ID: 26691307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insoluble TATA-binding protein accumulation in Huntington's disease cortex.
    van Roon-Mom WM; Reid SJ; Jones AL; MacDonald ME; Faull RL; Snell RG
    Brain Res Mol Brain Res; 2002 Dec; 109(1-2):1-10. PubMed ID: 12531510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment.
    Persichetti F; Trettel F; Huang CC; Fraefel C; Timmers HT; Gusella JF; MacDonald ME
    Neurobiol Dis; 1999 Oct; 6(5):364-75. PubMed ID: 10527804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract.
    Hazeki N; Nakamura K; Goto J; Kanazawa I
    Biochem Biophys Res Commun; 1999 Mar; 256(2):361-6. PubMed ID: 10079189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers.
    Hoffner G; Island ML; Djian P
    J Neurochem; 2005 Oct; 95(1):125-36. PubMed ID: 16181417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein aggregation in Huntington's disease.
    Hoffner G; Djian P
    Biochimie; 2002 Apr; 84(4):273-8. PubMed ID: 12106904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for a recruitment and sequestration mechanism in Huntington's disease.
    Preisinger E; Jordan BM; Kazantsev A; Housman D
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1029-34. PubMed ID: 10434302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology.
    Scherzinger E; Sittler A; Schweiger K; Heiser V; Lurz R; Hasenbank R; Bates GP; Lehrach H; Wanker EE
    Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4604-9. PubMed ID: 10200309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cells exposed to a huntingtin fragment containing an expanded polyglutamine tract show no sign of ion channel formation: results arguing against the ion channel hypothesis.
    Nørremølle A; Grunnet M; Hasholt L; Sørensen SA
    J Neurosci Res; 2003 Jan; 71(1):132-7. PubMed ID: 12478622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyglutamine expansion and Huntington's disease.
    Bates GP; Mangiarini L; Wanker EE; Davies SW
    Biochem Soc Trans; 1998 Aug; 26(3):471-5. PubMed ID: 9765898
    [No Abstract]   [Full Text] [Related]  

  • 19. The enigma of Huntington's disease.
    Cattaneo E; Rigamonti D; Zuccato C
    Sci Am; 2002 Dec; 287(6):92-7. PubMed ID: 12469651
    [No Abstract]   [Full Text] [Related]  

  • 20. A huntingtin-associated protein enriched in brain with implications for pathology.
    Li XJ; Li SH; Sharp AH; Nucifora FC; Schilling G; Lanahan A; Worley P; Snyder SH; Ross CA
    Nature; 1995 Nov; 378(6555):398-402. PubMed ID: 7477378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.